Current Treatment Options in Neurology

, Volume 9, Issue 4, pp 249–255 | Cite as

Identification and treatment of acute repetitive seizures in children and adults


Opinion statement

Acute repetitive seizures are a predictable component of a patient’s seizure disorder, historically distinct from the patient’s other epileptic seizures in type, frequency, severity, or duration, and with an onset easily recognized by caregiver and physician. Onset has a consistent predictable component (such as aura or prodrome, which may be a convulsive or nonconvulsive symptom, or characteristic single or multiple seizures) that is predictably and temporally linked to subsequent seizures. Typically there is recovery between seizures. Episodes may or may not progress to a prolonged seizure or to status epilepticus but may be predictable for each patient based on history. Acute repetitive seizures may include any type of epileptic seizure and may occur at any age. Other terms for acute repetitive seizures include cluster, serial, recurrent, or crescendo seizures. Treatment should only be administered by caregivers who in the opinion of the prescriber are capable of monitoring the clinical response and recognize when the response is such that immediate professional evaluation or care is necessary. Caregivers must be comfortable so that they feel capable of recognizing when and how to treat. The prescriber and caregiver should have a written plan on when to treat and what to observe and do after treatment. The most immediate treatment for out of hospital care and the only US Food and Drug Administration-approved product for acute repetitive seizures is rectal diazepam gel administered at a dose of 0.2 to 0.5 mg/kg, depending on age and weight (Class I evidence). Treatment may produce central nervous system depression. Oral, buccal, and sublingual benzodiazepines (lorazepam, diazepam) are also used for treatment but only if the risk of aspiration is not a concern and recognizing that absorption time will be increased (Class III evidence). Nasal benzodiazepine products, available in some countries, are not yet available in the United States.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981, 22:489–501.CrossRefGoogle Scholar
  2. 2.
    Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epilepsies and epileptic syndromes. Epilepsia 1989, 30:389–399.CrossRefGoogle Scholar
  3. 3.
    Engel J Jr: ILAE Commission Report. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001, 42:796–803.PubMedCrossRefGoogle Scholar
  4. 4.
    International League Against Epilepsy. Accessed April 30, 2007.
  5. 5.
    Gastaut H, Broughton R: Epileptic Seizures: Clinical and Electrographic Features, Diagnosis, and Treatment. Springfield, IL: Charles C. Thomas; 1972:143–146.Google Scholar
  6. 6.
    Shinnar S, Berg AT, Moshe SL, et al.: How long do new-onset seizures in children last? Ann Neurol 2001, 49:659–664.PubMedCrossRefGoogle Scholar
  7. 7.
    Gastaut H, in collaboration with an international group of experts: Dictionary of Epilepsy. Geneva: World Health Organization; 1973.Google Scholar
  8. 8.
    Working Group on Status Epilepticus: Treatment of status epilepticus. JAMA 1993, 270:854–859.CrossRefGoogle Scholar
  9. 9.
    Bergen DC: Do seizures harm the brain? Commentary. Epilepsy Curr 2006, 6:117–118.PubMedCrossRefGoogle Scholar
  10. 10.
    Kapur J, Macdonald RL: Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 1997, 17:7532–7540.PubMedGoogle Scholar
  11. 11.
    Jordan KG: Status epilepticus. A perspective from the neuroscience intensive care unit. Neurosurg Clin N Am 1994, 5:671–686.PubMedGoogle Scholar
  12. 12.
    Haut SR, Shinnar S, Moshe SL, et al.: The association between seizure clustering and convulsive status epilepticus in patients with intractable complex partial seizures. Epilepsia 1999, 40:1832–1834.PubMedCrossRefGoogle Scholar
  13. 13.
    Alldredge BK, Gelb AM, Isaacs SM, et al.: A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001, 345:631–637.PubMedCrossRefGoogle Scholar
  14. 14.
    Dreifuss FE, Rosman NP, Cloyd JC, et al.: A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med 1998, 338:1869–1875.PubMedCrossRefGoogle Scholar
  15. 15.
    Cereghino JJ, Mitchell WG, Kriel RL, et al.: Treating repetitive seizures with a rectal diazepam formulation. A randomized study. Neurology 1998, 51:1274–1282.PubMedGoogle Scholar
  16. 16.
    Mitchell WG, Conry JA, Crumrine PK, et al.: An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance. Epilepsia 1999, 40:1610–1617.PubMedCrossRefGoogle Scholar
  17. 17.
    Kriel RL, Cloyd JC, Pellock JM, et al.: Rectal diazepam gel for treatment of acute repetitive seizures. Pediatr Neurol 1999, 20:282–288.PubMedCrossRefGoogle Scholar
  18. 18.
    Cereghino JJ, Cloyd JC, Kuzniecky RI, et al.: Rectal diazepam gel for treatment of acute repetitive seizures in adults. Arch Neurol 2002, 59:1915–1920.PubMedCrossRefGoogle Scholar
  19. 19.
    O’Dell C, Shinnar S, Ballaban-Gil KR, et al.: Rectal diazepam gel in the home management of seizures in children. Pediatr Neurol 2005, 33:166–172.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Oregon Health and Science UniversityPortlandUSA

Personalised recommendations